Ординатура / Офтальмология / Английские материалы / Essentials in Ophthalmology Glaucoma_Grehn, Stamper_2006

Subject Index

189

Fibrodegenerative layer 174

–

preperimetric 36, 37

Guidelines for Economic Evalua-

Fibroleukin 148

–

primary 174

tion of Pharmaceuticals 127

Fibronectin 145

– primary angle closure glau-

Guidelines for the Pharma-

Fibrovascular layer 174

coma see PACG

ceutical Industry on Prepara-

Filtering bleb see FB

–

primary open-angle see

tion of Submissions to the

5-Fluorouracil 163, 168

POAG

Pharmaceutical Benefits

Fluorescein 49

–

probability 40

Advisory Committee 127

–

angiography 75

–

progression 74, 157

Fourier analysis 77

–

progressive 38

Fuchs dystrophy 66

–

pseudophakic 175

H

–

quality of life 131

Health Belief model 42

–

risk of 39, 40

–

secondary 174

Health care system 101, 103, 125

G

–

severe 36

Health economics 123

Ganglion cells 73, 74, 76, 77

–

severity 30

–

activities 124

GAT (Goldmann applana-

–

surgery 109, 176

–

journals 124

tion tonometry) 48–50, 53,

–

therapy 137

–

purpose 123

55–61, 65

–

uveitic 175

Health status change 125

Gene therapy 137, 143, 146, 148

Glaucoma implant 173, 181

Heidelberg Retina Tomograph

–

Caldesmon 144

–

Ahmed 173, 175–177, 180,

see HRT II

GFP (green fluorescent protein)

182

Hep II 145, 146

144

–

Baerveldt 173, 175–177, 180,

Heparan sulfate proteoglycan

Giant vacuoles 7

182

145

Glaucoma 12, 91

–

double-plate 173, 175

High ocular perfusion 53

–

abnormal resistance 28

–

failure 173

Homeostatic setpoint 14, 16, 18

–

abnormalitites 28

–

Krupin 173, 175–177

Hook’s Law 48

–

advanced 36, 37, 79

–

Molteno 173–178, 182

Hospital

–

aphakic 175

–

single-plate 173, 175

–

academic 130

– associated with corneal trans-

Glaucoma risk calculator 40,

–

non-academic 130

plants 175

43, 44

HRT(Heidelberg Retina Tomo-

–

care 123, 128, 131

–

benefits to society 42

graph) II 157–159, 163

– – in developing countries of

–

disadvantages 42

Humphrey visual field see HVF

Asia 109

–

OHTS 41, 42

HVF (Humphrey visual field) 86

–

childhood - 47, 61

– The Devers Ocular Hyperten-

11β-hydroxysteroid dehydro-

–

chronic 95

sion to Glaucoma 40, 41, 43

genase I 142

–

congenital with iridocorneal

Glaucomatous damage 47, 48,

Hyaluronic acid 145

dysgenesis 175

73–77, 80, 82, 86, 131

Hypermetropic people 114

–

developing 42, 44, 81

Glaucomatous optic nerve dam-

Hypertensive phase 182

–

diagnosis 47, 48, 73, 80, 85,

age 83

Hyphema 181

86

Glaucomatous optic neuropathy

Hypotony 173, 175, 176, 182

–

early 36, 79, 80

see GON

–

early detection 74, 83

Glycoprotein 142

–

high-risk group 129

Goblet cells 162

I

–

impact 114,

Goldmann applanation tonom-

–

management 70, 92, 116, 153

etry see GAT

ICD (International Classification

–

medication, total costs 129

Goldmann’s principle 71

of Diseases)-9 92

–

neovascular 173, 180, 181

GON (glaucomatous optic neu-

Imbert-Fick Law 48

–

normal-tension 65

ropathy) 111

Implantable sensor 153

– open angle see OAG

Gonioscopy 14, 48

Increased stretch 14

–

pathogenesis 47

Grant’s studies 23, 24, 26–28

Inflow suppression 148

190

Subject Index

International Classification of

Mechnotransduction 4, 17

K

Diseases see ICD

Media opacity 81

Interocular test 86

Keratokonus 61

Medication

Intraocular infection 181

Keratoplasty penetrating 180

–

anti-fibrotic 175

Intraocular inflammation 58

Kleinert’s studies 28, 29

–

antiglaucoma 179

Intraocular pressure see IOP

Kronfeld’s aqueous withdrawal

–

antihypertensive 100

Intraocular surgery 65, 66, 153

test 22

–

nonadherence 100

IOP (intraocular pressure)

Laminin 146

Medication-possession ratio

–

control 183

92, 95

–

cyclic 14

MEDLINE 95

–

– determining resistance

MfPERG (multifocal pattern

L

characteristics 16

electroretinogram) 83

–

increasing 9, 14, 24, 25

Langham’s pneumotonography

MfVEP (multifocal VEP) 73,

–

– induced distention 18, 21

(PTG) 49

84–86

–

– induced resistance 25, 27

Laser endophotocoagulation

Microcyst 160

– – induced trabecular stretch-

181

–

intraepithelial 167

ing 8, 29

Laser in situ keratomileusis see

–

stromal 168

–

lowering drug therapy 138,

LASIK

Micro-economic evaluation 125,

147

Laser trabeculoplasty 130, 131

128

–

measurement 47, 58–60, 67,

Laser-scanning ophthalmoscopy

Microparticle 137, 152

69

158

Mitomycin C see MMC

–

– methods 48

Laser-scanning microscopy 168

MMC (mitomycin C) 109, 116,

–

– procedure 51

LASIK (laser in situ keratomi-

117, 159, 163, 165, 167, 174,

–

– techniques 153

leusis) 47, 56

182

–

oscillations 19

–

myopic 56

MLCK (myosin light-chain

–

postoperative 174

–

post56, 58, 61

kinase) 138, 140

–

reduction 36, 41, 138

–

pre56, 58, 61

MMP (matrix metalloprotein-

–

transients 8, 12

Latanaprost 146–148

ase) 146, 148

Iridectomy 24, 109, 181

Latrunculin (LAT)

–

-2 143

–

laser 109

–

A 141, 142

Monotherapy 97, 98

–

peripheral 183

–

B 140, 141, 142

Moorfields Laser, Medicine,

–

surgical 109

Lectin 152

Surgery see LMS

Iridoplasty 109

Lens depression 25, 26

Mucoadhesive 150

–

laser 109, 115

Lens extraction 116, 117

MYOC 142

Iridotomy 25, 109, 114

LGN 74

Myopia 114

–

laser 109, 112

Liposome 137, 151, 152

Myosin light-chain kinase see

– laser peripheral see PI

LMS (Moorfields Laser, Medi-

MLCK

–

surgical 109

cine, Surgery) 116

Ischemia 47

Local anesthesia 49

N

Nanoparticle 137, 152

J

M

NCT (non-contact tonometry)

Journal of Health Economics

Magnocellular damage paradigm

49, 56, 57

124

74

Nerve fiber layer see NFL

Juxtacanalicular cells 7, 17, 21

Magnocellular stream 73

New Jersey Medicaid Program

Juxtacanalicular space 9, 10

Maklakof tonometry 48, 49

95

Juxtacanalicular tissue 138

Markov model 127, 139, 131

NFL (nerve fiber layer) 83

Matrix metalloproteinase see

Niosome 137, 151, 152

MMP

Nitric oxide see NO

Subject Index

191

Nitrovasodilator 147, 148

Pigmented epithelium (PE) 149

P

NNT (number needed to treat)

Pilocarpine 16, 22, 29, 32

42, 114

PAC (primary angle closure)

Pneumatonometry 53, 65–68,

NO (nitric oxide) 147

111, 113, 115

71

Non-contact tonometry see NCT

–

incidence 112

POAG (primary open-angle

Non-invasive tonometry 48

–

prevalence 112

glaucoma) 3, 37, 83, 92, 93,

Nonocular hypotensive prescrip-

–

risk factors 113

97, 109, 110, 113–117, 130,

tion 101

PACG (primary angle-closure

138, 142

Nonpigmented epithelium

glaucoma) 109–114, 117, 119

Polypropylene 182

(NPE) 149

PACS (primary angle-closure

Population attributable risk see

Nor-binaltorphimine (nor-BNI)

suspect) 111, 115

PAR

149

Panretinal ganglion cell damage

Primary angle closure see PAC

Normal-tension glaucoma 47

82

Primary open-angle glaucoma

Panretinal photocoagulation

see POAG

180

Prostaglandin (PG) 96–99, 137,

PAR (population attributable

146, 148, 173

O

risk) 115

–

pathways 150

OAG (open-angle glaucoma) 12,

Paracentesis 116

Protein 138

37, 92, 96, 98

Parvocellular system 73, 74

–

C3 143, 145

Ocular hypertension see OH

PASCAL tonometer 51, 52, 60,

–

Caldesmon 144, 145

Ocular Hypertension Treatment

61

–

cytoskeletal 138

Study see OHTS

Pattern ERG see PERG

– green fluorescent see GFP

Ocular insert 152

Penetration enhancer 152

–

junctional 138

Ocular irritation 146

PERG (pattern ERG) 73, 76–80,

–

phosphotyrosine 141

Ocular vasculature 148

82, 83, 85

PSD 43

OH (ocular hypertension) 30,

–

amplitude 83

Pseudophakic bullous kerato-

36–38, 40–43, 74, 75, 78, 92,

–

Freiburg paradigm 81, 83

pathy 179

93, 95, 98, 99, 115, 130, 131

–

ratio 83

PubMed search service 95, 98

–

medication 44, 92–94

Pericardium 181

Pulsatile aqueous flow 6, 10,

–

therapy 102

Perimetry 75, 76, 129

12–14, 22, 28, 29

OHTS (Ocular Hypertension

Perkins aplanation tonometer

–

resistance 23

Treatment Study ) 36, 37,

67, 68

39–43, 74, 114

Peroxynitrite 148

κ-opioid receptor antagonist 149

Persistence 91, 96–103

Q

OPA (cardiac pulsation) 52, 53

Peusophakia 180

Open-angle glaucoma see OAG

Phacoemulsification 117

QALYs (Quality-Adjusted Life

Ophthalmoscopy 48, 129

Pharmaceutical industry 117

Years) 126, 127, 130

Opioid 137, 149

Pharmacoeconomics 125, 129

QAYV (Quality Adjusted Years

Optic disc progression 44

Phenylephrine drops 174

of Vision) 129

Optic nerve 109

Pheochromocytoma cells 150

Quigley model 110

–

damage 47

PhNR (photopic negative re-

Optical coherence tomography

sponse) 76

75

Photopic negative response see

R

Over-filtration 162, 167

PhNR

RBC (red blood cells) 10

Over-testing 131

Physician-patient communica-

tion 101

–

reflux 11

PI (laser peripheral iridotomy)

RCM (Rostock Cornea Module)

115, 116

157–159, 164, 168

Pigmentary dispersion syn-

Red blood cells see RBC

drome 43

Retinal ganglion cells 47